Ask AI
Practice Changing Evidence for CAR T Cells

CE / CME

Expert Insights on the Most Practice-Changing Evidence for CAR T-Cell Therapy Across Hematologic Malignancies

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: November 10, 2025

Expiration: May 09, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in explaining the rationale and mechanisms behind dual-targeting CAR T-cell therapy to patients and colleagues?

2.

When counseling a patient with MZL about lisocabtagene maraleucel, what would you tell them was the primary result of the phase II TRANSCEND FL study MZL cohort?

3.

Patient Case: 62-Yr-Old Woman With R/R MM



  • A 62-yr-old woman with multiple myeloma was previously treated for newly diagnosed disease with quad-based therapy

    • Treatment included a CD38 mAb, a proteasome inhibitor, and an immunomodulatory agent



  • She is now experiencing relapse while on lenalidomide maintenance

Based on current indications and clinical evidence, which CAR T-cell therapy would be an appropriate treatment option for this patient?

4.

When counseling a patient who is considering cilta-cel, which boxed warning adverse event should you make sure to discuss with them and their caregiver?